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Single-cell mass cytometry and transcriptome
proﬁling reveal the impact of graphene on human
immune cells
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Understanding the biomolecular interactions between graphene and human immune cells is a
prerequisite for its utilization as a diagnostic or therapeutic tool. To characterize the complex
interactions between graphene and immune cells, we propose an integrative analytical
pipeline encompassing the evaluation of molecular and cellular parameters. Herein, we use
single-cell mass cytometry to dissect the effects of graphene oxide (GO) and GO functio-
nalized with amino groups (GONH2) on 15 immune cell populations, interrogating 30 markers
at the single-cell level. Next, the integration of single-cell mass cytometry with genome-wide
transcriptome analysis shows that the amine groups reduce the perturbations caused by GO
on cell metabolism and increase biocompatibility. Moreover, GONH2 polarizes T-cell and
monocyte activation toward a T helper-1/M1 immune response. This study describes an
innovative approach for the analysis of the effects of nanomaterials on distinct immune cells,
laying the foundation for the incorporation of single-cell mass cytometry on the experimental
pipeline.
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The development of nanomaterials for medical and diag-nostic applications1 is one of the most promising frontiersof nanotechnology. Graphene, a single layer of hexagonally
arranged carbon atoms, and graphene oxide (GO), the oxidized
form of graphene, are carbon nanomaterials of extraordinary
physicochemical properties and a biocompatible proﬁle that
enables their utilization in biomedical applications2–4. However,
the impact of GO exposure on the immune system remains
unclear5–7. Differences among reports could be attributed to the
variability in the physicochemical characteristics of materials used
in terms of lateral dimensions, surface functionalization, and
chemical purity and deserves further investigation8–10.
GO can be rich in functional groups such as epoxy and
hydroxyl groups, which facilitate its surface modiﬁcations
increasing its biocompatibility. GO has been investigated in a
continuously growing number of medical applications11, 12.
However, the main limitation in using GO in nanomedicine is its
biocompatibility. As such, the evaluation of the immune pertur-
bations induced by nanoparticles is an essential prerequisite.
On the other hand, speciﬁc toxic effects of graphene-based
materials on cancer cells support its use in nanomedicine13, 14, for
example, as an inhibitor of cancer cell metastasis15 or as a passive
tumor cell killer in leukemia16.
As mentioned above, the effects played by physicochemical
characteristics of nanomaterials in terms of lateral dimension,
functionalization, and purity are still under discussion. In this
context, the chemical modiﬁcations of graphene can play a role in
the impact of these nanoparticles on the immune system8. It was
already reported that functionalization can reduce the toxicity by
changing the ability of graphene to modulate the immune
response6. Similarly, the cyto- and genotoxicity of reduced GO
(rGO) sheets on human mesenchymal stem cells were found to
depend on the lateral dimensions of the materials, ultra-small
sheets being more toxic17, 18. Studies have also shown that the
aspect ratio of the graphene sheets is an important factor to
consider. For instance, rGO affects cell viability only at very high
concentration (i.e., 100 µg ml−1), while single-layer GO nanor-
ibbons display signiﬁcant cytotoxic effects at 10 µg ml−119.
Moreover, a direct impact on the antibacterial activity or on
reproduction capability of mice inﬂuenced by the aspect ratio of
GO has been reported19–21. The possibility to rationally design
graphene materials with different physicochemical characteristics
could expand further their application in medicine22.
The understanding of the complex interactions between
nanoparticles and immune cells is hindered by insufﬁcient
implementation of high-throughput, deep phenotyping technol-
ogies in the ﬁeld23–26. The immune system is a sophisticated
machine meant to protect the body against injury, pathogens, or
tumors. Its dysfunction can induce pathologies such as auto-
immune diseases, allergies, and cancer27, 28. Revealing the inter-
actions of different GOs with this complex system still remains a
challenge.
Such a study should include tools that permit the multiplex
analysis of cell type, activation status, and release of soluble
mediators with stimulatory and inhibitory properties28, 29.
Flow cytometry has been primarily used to address single-cell
behavior. Recently, a tool employing mass spectrometry has been
developed to leverage the precision of ﬂow cytometry analysis.
The combination of the two techniques, termed single-cell mass
cytometry (CyTOF), allows the simultaneous measurement of
more than 40 cellular parameters at single-cell resolution with
over 100 available detection channels30, 31.
Compared to ﬂuorescence-based cytometry, mass cytometry
employs element-tagged probes that enable the discrimination of
elements according to their mass/charge ratio (m/z), with mini-
mal overlap and background cellular signal. All these attributes
simplify the large panel experimental design, thus uniquely
enabling high-dimensional cytometry experiments that would not
be possible otherwise30, 32–34.
In the present work, we demonstrate the use of single-cell mass
cytometry together with whole-transcriptomic analysis to dissect
the immunological effects of nanomaterials on individual cells.
Our results emphasize the importance of the functionalization on
enhancing the biocompatibility of GO-based nanomaterials.
Notably, only the amino-functionalized GO was able to induce a
speciﬁc monocytoid dendritic cell (mDCs) and monocyte acti-
vation skewed toward a T helper (Th)-1/M1 response. These
ﬁndings are starting points for the development of nanoscale
platforms in medicine as immunotherapeutics, vaccine carrier, or
nanoadjuvant tools.
Results
Graphene synthesis, functionalization, and characterization.
Thin GO ﬂakes (single to few graphene layers) and GO surface-
functionalized with amino groups (GONH2)35 via epoxide ring
opening, using triethyleneglycol (TEG) diamine, were investi-
gated (see Methods section). We have previously shown that the
epoxide ring opening reaction is a versatile strategy to functio-
nalize GO in a controlled manner. This reaction targets the
epoxide groups, without causing reduction of the starting GO
material35. The detailed physicochemical characterization of both
GO and GONH2 is reported in the Supporting Information
(Supplementary Fig. 1). Brieﬂy, the 2D material morphology was
studied by both TEM and AFM (Supplementary Fig. 1a–d). These
techniques indicated that the lateral sheet dimensions of both GO
and GONH2 ranged between 50 nm and 1 µm. The vast majority
of the ﬂakes, both for GO and GONH2, had lateral dimensions
smaller than 300 nm (73% and 62%, respectively, according to
TEM measurements). The height distributions obtained by AFM
revealed that GO sheets had thicknesses corresponding to single
and few (2–3) layers. The GONH2 sheets were ~3 times thicker
than the non-functionalized GO. The increased thickness of
graphene-based materials following functionalization has been
previously reported and is attributed to the reaction processing
and the presence of functional groups on the sheet surface36, 37.
Raman spectroscopy evidenced the presence of the character-
istic D and G bands (1330 and 1595 cm−1, respectively) in both
GO materials, conﬁrming their graphenaceous structure. Further-
more, we observed that both GO and GONH2 exhibited a 2D
band that was of low intensity and of broad linewidth. This
correlated with the oxidation and exfoliation of graphite to GO in
the modiﬁed Hummers’ method, due to increased defects in the
graphene sheets38, 39. Therefore, the analysis of this peak is not a
reliable indicator to draw conclusions regarding the presence of
single-layer GO, even though it is possible in the case of
graphene40 and rGO41. Nonetheless, we examined the I(D)/I(G)
ratio, a commonly used parameter to assess disorder42. When
comparing GO and GONH2, the I(D)/I(G) ratio did not increase
signiﬁcantly, since the epoxy ring opening reaction conditions
used for amination were shown to not add further defects to the
GO surface35, 38. It was reported that a strong reduction process
results in an increased I(D)/I(G) ratio due to the predominance of
small sp2 carbon domains in the graphene lattice43. These results
are consistent with the maintenance of the oxidation degree of
GO after functionalization, which was demonstrated in a previous
study by XPS analysis of the C-O binding energy peak, before and
after functionalization with TEG diamine30. We found that the
O/C ratio decreased from 0.44 to 0.38 after GO covalent
modiﬁcation. It was reported that ethylenediamine is able to
reduce GO, but the mechanism involves the formation of a ﬁve-
membered ring that is not possible using TEG diamine44.
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Stronger agents like hydrazine or plant extracts are necessary to
achieve an efﬁcient reduction of GO44, 45. Amino functionaliza-
tion was conﬁrmed by FT-IR spectroscopy, which showed a clear
difference between GO and GONH2. Importantly, the presence of
an extra band in the 1260–1330 cm−1 range in GONH2 compared
to the GO samples can be explained by the amine C-N stretching
and C-H bending. Furthermore, the presence of a new band
around 2900 cm−1, indicative of the presence of the aliphatic C-H
stretching, supported the successful functionalization of GO by
epoxide ring opening due to the presence of the TEG chain. These
results provided evidence of the successful synthesis of GO and
GONH2 studied in our experiments35, 46.
Dissecting the immunological impact of graphene with
CyTOF. We used single-cell mass cytometry to analyze simulta-
neously 30 markers discriminating distinct subpopulations of
peripheral blood mononuclear cells (PBMCs), in order to
understand the response to nanomaterial exposure. CyTOF
analysis allowed us to check the differential viabilities of 15
immune cell subpopulations exposed to GO and GONH2 for
24 h. A concentration of 50 µg ml−1 was chosen for these
experiments because it was identiﬁed as an appropriate con-
centration for different GO-based biomedical applications9, 23, 47.
One qualitative difference between ﬂow cytometry and mass
cytometry is the absence in the latter of the spectral overlap that
complicates the analysis of ﬂuorescence data. Another advantage
is the absence of cell-dependent background signals in the mass
cytometry data48.
Immune cell populations are identiﬁed according to the
expression proﬁle of cluster of differentiation (CD) markers
present on the cell surface. When immune cells go through
different stages of maturation and differentiation, the CD marker
proﬁles change. Mass cytometry with its high dimensionality is an
ideal approach to simultaneously characterize several cell
markers. CyTOF could analyze the effect of GO and GONH2
on a wide variety of immune cell populations, determining also
different maturation and activation stages. To reduce the
dimensionality of the data set, we used SPADE (spanning tree
progression analysis of density-normalized events) clustering
algorithm (Fig. 1a), as reported by Bendall et al.48 To construct
the SPADE tree, we used 11 cell surface markers in treated and
untreated healthy human PBMCs to identify the major immune
cell populations. Sixteen additional markers were acquired.
Among them, ﬁve extracellular markers were used to better
deﬁne cell subpopulations. The remaining 11 intracellular makers
were employed for the cytokine detection, and were excluded
from the tree construction. Each node in the two dimensional
representation describes an n-dimensional boundary encompass-
ing a population of phenotypically similar cells. The size of each
node in the tree is proportional to the number of cells within each
population. Node color is scaled to the median intensity of
marker expression. The approach uses a minimum-spanning tree
algorithm, in which each node of cells is connected to its most
related node as a means to convey the relationships between the
cell clusters. As a result, the 15 manually assigned populations
were segregated in 200 nodes of distinct but logically inter-
connected populations. These trees provide a convenient
approach to map complex n-dimensional relationships into a
representative 2D structure48.
However, it is well known that the SPADE algorithm is
inherently stochastic and the estimate of the cell populations can
differ in across repeats of the analyses. This limitation of SPADE
is also supported by the continuous development of efﬁcient
algorithms49. To corroborate the robustness of our conclusions,
the SPADE analysis was performed three times.
As reported in Supplementary Table 1, the event counts of the
main immune subpopulations are similar in the different
algorithm runs, conﬁrming the robustness of the SPADE data
analysis.
In this analysis, cisplatin (CIS) was used as marker for
viability50. CIS is a molecule able to enter into the late apoptotic
and necrotic cells that have lost membrane integrity. The SPADE
tree clustering shows that GO induced cytotoxicity in all B-cell
subpopulations (Fig. 1a). Monocytes and activated Th cells were
also affected by the presence of GO. On the other end, the
functionalized GONH2 signiﬁcantly reduced CIS signal in all
subpopulations (Fig. 1b), CIS median expression in distinct
subpopulations. Moreover, GONH2 was three times more
biocompatible in all B-cell populations than non-functionalized
GO. This effect was also evident in activated cytotoxic T
lymphocytes (CTLs) and Th cells, where GONH2 did not induce
high levels of toxicity. Overall, the functionalization of GO
enhanced its biocompatibility toward the immune populations
analyzed (Fig. 1b) with the exception of natural killer (NK) cells
and memory CTLs (see Methods section for gating strategy), in
which both GO and GONH2 induced minimal cytotoxicity. These
results emphasize the importance of amino functionalization in
enhancing the biocompatibility of GO-based nanomaterials.
Interestingly, the same type of functionalization used to modify
GO was previously found to improve the biocompatibility of
other nanomaterials such as carbon nanotubes24, 25.
Cytokine analysis on several immune cells with CyTOF. We
further applied CyTOF to understand the functional impact of
GO and GONH2 on the immune subpopulations. The heat map
visualizes the median expression values of all intracellular mar-
kers used for each immune population (Fig. 2a). GO caused a
broad, non-cell-speciﬁc activation triggering the production of all
cytokines analyzed in a variety of cell populations (Fig. 2a), while
GONH2 was more speciﬁc affecting, for instance, the production
of only few cytokines in selected cell subpopulations. Among
T cells, GO induced the secretion of interleukin (IL) 2, 4, and 5 by
Th and CTLs (Fig. 2b). Conversely, GONH2 selectively induced
the production of IL2 by activated T cells and the production of
tumor necrosis factorα (TNFα) in several cell subpopulations.
Moreover, GONH2 did not affect the synthesis of IL5 by T cells,
and only modestly effected that of IL4 (Fig. 2b). IL4/IL5 are
markers of Th2 polarization, while TNFα/IL2 indicate Th1 dif-
ferentiation. Thus, it appears that GONH2 elicits a polarized Th1
immune response and a non-speciﬁc Th response. GONH2
tropism for Th1 cytokines was mirrored in B-cells (Fig. 2c).
Moreover, GONH2 was able to induce dendritic cell and mono-
cyte activation skewed toward a M1 response, as demonstrated by
increased production of classic M1 cytokines such as TNFα, IL6,
and the CCR5 ligand CCL4 (MIP1β) (Fig. 2d)51, 52.
Th2 responses are involved in asthmatic reactions and
induction of allergy53. Moreover, Th2 responses (sustained by
M2 macrophages) favor cancer growth54. Conversely, Th1
responses (sustained by M1 macrophages) counteract cancer
development55, 56. In fact, intratumoral Th1 (but not Th2)
signatures have been invariably associated with favorable
prognosis and responsiveness to immunotherapy55, 57–62. These
data are of particular interest for further translational applications
of amino-functionalized GOs for possible immunotherapeutic
strategies or as a vaccine adjuvant. M1 cytokine production such
as IL6, TNFα, and MIP1β after treatment with GO and GONH2 is
represented in Fig. 3. Negative controls are reported in
Supplementary Fig. 2. We found increased expression of IL6 in
monocytes, mDCs (monocytoid dendritic cells), and activated Th
cells (red nodes) mediated mainly by GONH2 (Fig. 3a). As
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expected, TNFα secretion was mediated by GONH2 in mono-
cytes, mDCs, activated CTLs, Th cells, and in NK cells (Fig. 3b).
The expression of MIP1β was clearly observable in monocytes,
mDCs, and activated Th in response to both GOs. However, as
previously mentioned, the median intensity was higher in
GONH2-treated samples. GO, instead, induced MIP1β expression
also in B-cell populations (Fig. 3c).
SPADE visualization could give further information on the
impact played by GOs on single cells through heterogeneity
analysis within nodes. Indeed, not all the cells in the same family
display the same cytokine secretion intensity, underlining possible
different maturation and/or activation stages. An example is
given by TNFα secretion by CD16− NK cells treated with GONH2
(Fig. 3b), where half of the nodes included did not secrete TNFα.
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Fig. 1 Cell viability analysis using CIS reagent with CyTOF. PBMCs were treated with GO and GONH2 at the concentration of 50 µg ml−1. a The SPADE tree
plots show the different gated immune cell subpopulations. The size of each cluster in the tree indicates the relative frequency of cells that fall within the
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Graphene activity evaluation on a single-cell resolution.
Overall, the SPADE data suggest a cross-talk between monocytes/
mDCs and CTLs/Th cells that could sustain a speciﬁc cell-
mediated immunity, avoiding humoral response and possible
hypersensitivity. However, the SPADE visualization fails to
preserve the single-cell resolution of the mass cytometry data. For
this reason, we applied a second dimensionality reduction
method called viSNE, which is a computational approach suitable
for the visualization of high-dimensional data with single-cell
resolution63. By this approach, immune cell phenotypes are
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projected onto a biaxial plot space according to the similarity of
their multidimensional phenotypic expression vector. Thus,
viSNE clusters the single-cell events into populations according to
the 11 protein expression readouts used in the analysis (Fig. 4).
The viSNE analysis accurately identiﬁed helper and CTL T cells,
B cells, monocytes, and NK cells (Supplementary Figs. 3–6).
The naive, memory, and activated T-cell subpopulations and the
B-cell subpopulations were also identiﬁed (Supplementary
Figs. 3–5).
We further exploited the viSNE analysis to investigate the
single-cell cytokine proﬁle in response to GO and GONH2
treatment. This analysis conﬁrmed the subpopulations and
cytokine expression proﬁles obtained by the SPADE approach
and supports the main conclusion that the amino functionaliza-
tion of GO signiﬁcantly increases cell biocompatibility and
polarizes a speciﬁc cell activation toward a T helper-1/M1
immune response not affecting the B-cells response. Instead, GO
incubation caused an increase in B-cell counts correlating with an
increase in IL2 secretion mostly by the plasma B cells and a
reduction of monocytes (Supplementary Figs. 5, 6). The single-
cell resolution obtained with the viSNE analysis evidenced a
heterogeneity in the cytokine expression proﬁle within the same
subpopulation (TNFα, IL6, IL5, IL4, and IFNγ) (Fig. 4), revealing
a heterogeneous response after GO and GONH2 treatment.
Cross conﬁrmation of single-cell analysis. Since single-cell mass
cytometry has not been previously applied to nanomaterials, we
corroborated the analysis with several classical techniques to
analyze cell apoptosis, necrosis, and activation and cytokine
secretion. Analysis of human PBMCs using ﬂow cytometry con-
ﬁrmed the trend observed with the CyTOF experiments.
Figure 5a displays the histograms related to apoptosis and
necrosis experiments (expression of Annexin V (apoptotic) and
PI (necrotic) positive cells after treatment with GO and GONH2)
using the same conditions reported for the CyTOF analysis
(P-value< 0.05). Data were also conﬁrmed by a dose-response
analysis (5, 25, and 50 µg ml−1) using 7-amino actinomycin D
(7AAD) to detect cells with compromised membranes (late
apoptotic and necrotic cells). High amounts of necrotic cells were
detected, suggesting a possible direct effect of GO on the cell
membrane that leads to extensive damage. These ﬁndings were in
agreement with a previous work in which we disclosed the mask
effect of GO9. As expected, the functionalization improved the
biocompatibility of GO with a reduction of necrotic events, from
42.0 to 24.7% (P-value= 0.045) (Fig. 5a). Similar results are
reported in Fig. 5b. Indeed, at the highest concentration used, we
found a reduction of necrotic events from 27.3 to 6.7% (P-value
= 0.039) in GONH2-treated samples. The improvement of bio-
compatibility mediated by GONH2 was conﬁrmed by hemolysis
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Fig. 4 Single-cell characterization of GO- and GONH2-treated PBMCs (viSNE analysis). Plots show the use of viSNE to obtain a comprehensive single-cell
view and to distinguish the PBMC subpopulations in the GO- and GONH2-treated cells. Plots show expression of the 19 proteins, nucleic acid intercalator
(CIS), and density measured per cell
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01015-3 ARTICLE
NATURE COMMUNICATIONS |8:  1109 |DOI: 10.1038/s41467-017-01015-3 |www.nature.com/naturecommunications 7
analysis in red blood cells (RBCs). Hemolysis is reported to be an
undesirable effect mediated by GOs at high concentrations64. The
release of hemoglobin from damaged RBCs after treatment with
increasing doses (5, 25, 50, and 100 µg ml−1) of GO and GONH2
was analyzed (Supplementary Fig. 7). The highest concentration
of GO was able to induce a signiﬁcant release of hemoglobin,
showing damage to RBCs. On the other hand, the functionalized
GONH2 did not damage RBCs at any of the concentrations
studied (Supplementary Fig. 7). However, this may be due to the
differences between the two material types in thickness and
quality of the suspension, as the GO sheets are dispersed more
homogeneously than GONH2.
Further activation analyses were performed by ﬂow cytometry,
measuring CD69 and CD25, early and late activation markers,
respectively (Fig. 5c). Total PBMCs were treated with both GO
and GONH2 at the concentration of 50 µg ml−1 for 24 h. GONH2
induced higher (15.03%, P-value 7.89E−05) expression of CD25
compared to GO (8.7%, P-value= 0.009) (Fig. 5c). A similar trend
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was observed for CD69 expression with 8.4% (P-value= 0.001)
and 5.8% (P-value= 0.012) of cells expressing the marker in
GONH2 and GO, respectively. Changes in cell diameter reﬂect the
status of immune cell activation, with larger size corresponding to
an active status. The effect of GO and GONH2 on cell size was
analyzed using Scepter 2.0. PBMCs were treated with GO and
GONH2 at the concentration of 50 µg ml−1 for 24 h. Figure 5d
shows the cell diameter of lymphocytes, inactivated monocytes
(Fig. 5d(i)), and activated monocytes (Fig. 5d(ii)). GONH2
induced higher changes in monocyte diameter compared to the
untreated sample. In line with previous results on the action of
GONH2, we found 2.65 × 104 cells with a diameter larger than
11.75 μm, compared to 9.78 × 103 cells for the control (Fig. 5d
(iii)). The effect of GONH2 was studied also by multiplex ELISA
on the PBMC supernatants. The secretion of classical Th1/M1
cytokines such as CCL5, IL6, IL1β, and TNFα increased
after stimulation with GONH2 but not GO treatment (Fig. 5e;
P-value< 0.05).
All data obtained through the use of classical techniques
conﬁrmed the CyTOF main ﬁndings, therefore supporting its use
as a robust technique for comprehensive analyses of
nanomaterial–immune cell interaction.
Whole-genome expression analysis on T cells and monocytes.
To obtain a higher intensity portray of the interaction between
nanomaterials and immune cells, we used the Illumina Beadchip
HumanHT-12 v4 genome-wide technology analyzing about
47,000 transcripts in GO- and GONH2-treated T lymphocyte
(Jurkat cells) and monocyte (THP1) cell lines as representative of
adaptive and innate immune responses, respectively. These cell
lines were incubated with GO and GONH2 (50 µg ml−1, 24 h) in
the same conditions used for the previous CyTOF experiments.
To compute the probability of genes being differentially expres-
sed, we used a random variance t-test as implemented in BRB
Array-Tools (Supplementary Data 1, 2). Results were controlled
for false discovery rate (FDR). We conﬁrmed that the functio-
nalization signiﬁcantly reduced (P-value< 0.001 and FDR< 0.05)
the magnitude of the perturbations induced by GO (Venn dia-
gram, Fig. 6a–c). Overall, the number of transcripts modulated by
GONH2 was less than one-third of the transcripts altered by GO.
Following the treatment with functionalized GONH2, 1163
transcripts were altered in T cells and 977 in monocytes as
compared with 4509 transcripts in T cells and 3528 in monocytes
in GO-treated samples (Fig. 6; Supplementary Data 1, 2). How-
ever, the effect of GONH2 was clearly more speciﬁc. Indeed, 2845
transcripts were modulated in both T-cell and monocytes by GO.
In contrast, only 390 transcripts were modulated in both treated
cells by GONH2 (Fig. 6a). Venn diagrams in Fig. 6b, c describe
the different modulation induced by GO and GONH2 in the
treated cells.
To provide a functional interpretation of the transcriptional
changes, we applied Ingenuity Pathway Analysis (IPA). The most
differentially affected canonical pathways in GO- compared to
GONH2-treated T cells and monocytes are shown in Fig. 6d while
the 20 top canonical pathways are shown in Supplementary Fig. 8.
While the perturbations induced by GO reﬂect the triggering of
cytotoxic mechanisms, the changes induced by GONH2 consist of
the selective immune activation of T cells and monocytes. Indeed,
the canonical pathways most signiﬁcantly affected by GO are
eukaryotic initiation factor 2 (EIF2) signaling, oxidative phos-
phorylation (OXPHOS), and mTOR signaling, all related to cell
metabolism and proliferative function. This effect is visible in
both cell types (Fig. 6d). More in detail, protein synthesis, as
indicated by the negative Z-score of the EI2F pathway, was
suppressed by GO treatment, in line with the induction of
apoptotic mechanism showed by the CyTOF and ﬂow cytometry
analyses. Conversely, the functionalized GONH2 induced a
coordinated induction of immune-activator pathways with
limited impact on cell metabolism. Almost all the top 20
canonical pathways modulated by GONH2 are related with
immune functions (Supplementary Fig. 8). Such pathways include
intracellular signaling implicated in the activation of T cells and
in the maturation and activation of monocytes (e.g., interferon
signaling, interferon regulatory factor (IRF) activation by pattern
recognition receptor (PRR), and antigen presenting and inﬂam-
masome pathways) (Fig. 6d; Supplementary Fig. 8). These
differences between the two GOs was conﬁrmed using the gene
set comparison tool in BRB Array-Tools as a scoring test to assign
the functional category deﬁnitions according to the Gene
Ontology database, with a P-value< 0.005 (Supplementary
Data 3, 4). The perturbation of the OXPHOS pathway found
also with IPA highlights the impact of GO on cell metabolism
(Supplementary Fig. 9a, b). The modulation of IFN signaling in
T cells and DC maturation pathway in monocytes induced by
GONH2 are represented in Supplementary Figs. 10, 11. Thus, GO
compared to GONH2 induces a stronger alteration of pathways
related to cellular replication and metabolism (Supplementary
Fig. 8; Supplementary Data 3, 4) with a downregulation of
OXPHOS pathway (Supplementary Fig. 9a, b). In summary,
GONH2 was conﬁrmed to upregulate immune activation path-
ways without disrupting intracellular homeostasis. A list of
immune-related genes modulated by GONH2 in T cells and
monocytes is reported in Fig. 6e. These genes include Th1
chemokines65 such as CXCL10 (CXCR3 ligand), CCL3, CCL3L3,
CCL4L1, CCL4L2, and CCL5 (CCR5 ligands), pro-inﬂammatory
cytokines such as TNFα and IL1β (Fig. 6e), and master regulators
of the cross-talk between innate and adaptive immune response
such as IRF1 and STAT1. To validate the Illumina Beadchip data,
we performed real-time PCR with highly speciﬁc TaqMan probes.
Again, IRF1, CCL3L3, IL1B, and CCL5 were consistently over-
expressed only after GONH2 treatment (Supplementary Fig. 12).
Remarkably, these genes (i.e., CXCR3/CCR5 ligands, and the
transcription factors STAT1 and IRF1) are central in the
induction of immune-mediated tumor rejection57, 60, 66 and their
overexpression in resected tumors has been associated with
favorable prognosis59, 61, 62. Such transcripts are upregulated in
tumors from patients who are more likely to respond to
immunotherapeutic approaches such as IL267, vaccine68, adoptive
therapies58, and checkpoint inhibition69. Moreover, the efﬁcacy of
cancer immunotherapy relies on the ability to trigger a Th1/M1
anti-tumor response through the induction of the expression of
the aforementioned transcripts54, 57. Recently, the use of different
kinds of nanomaterials as immune modulators for vaccine
adjuvant or immunotherapy applications have been
described70–73. Xu et al. proposed the use of polyethylene glycol
and polyethyleneimine functionalized GO as vaccine adjuvant.
Functionalized GO was found to promote the maturation of DCs,
through the activation of multiple toll-like receptor (TLR)
pathways while showing low toxicity74. In a similar and extensive
way, the current morphological and genomic analysis suggests
that GONH2 might enable the initiation and induction of
monocyte and DC activation, possibly through TLR/PRR
interactions. The results on GO underline how this material is
affecting mainly the intracellular metabolic processes such as the
OXPHOS and ribosomal activity in both T cells and monocytes in
a dose-dependent way. This action could enhance the membrane
damage and the reactive oxygen species (ROS) production
eventually leading to necrosis9, 75. This effect of GO was reported
also by other authors for cell lines and bacteria. Akhavan et al.77
for example, described the interaction of the sharp edges of
graphene sheets with the cell walls of bacteria and cell lines,
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01015-3
10 NATURE COMMUNICATIONS |8:  1109 |DOI: 10.1038/s41467-017-01015-3 |www.nature.com/naturecommunications
leading to the generation of ROS and cell wrapping76. However,
the mechanism associated with cytotoxicity of GO on primary
immune cells is likely more complex than in the case of other
types of mammalian (i.e., cancer cell lines) and bacterial cells
involving a direct impact on cell membrane or generation of ROS,
and it warrants future studies. Our data suggests that amino-
functionalized GO is likely to facilitate the differentiation of
monocytes into monocyte-derived DCs (moDCs). MoDCs pulsed
with certain tumor-associated antigens (and eventually prompted
with functionalized GO) could expand tumor-speciﬁc T-cytotoxic
cells to elicit anti-tumor immunity73, 78, 79.
In conclusion, we propose a high-throughput strategy for the
characterization of complex interactions between nanomaterials
and the plethora of immune cell populations. The analysis of
multicellular systems where cells carry out a diverse array of
complex, and specialized functions is still a big challenge33.
Single-cell mass cytometry enters successfully in this context with
its unique capacity of simultaneously resolving a large amount of
probes on a per-cell basis at high acquisition rates, thereby
providing researchers the ability to phenotypically and function-
ally proﬁle different cell subpopulations. This technology allows
the sophisticated analysis of multiple immune cell interactions
with nanomaterials, while overcoming the limitations of spectral
overlap present in ﬂow cytometry and revealing all the possible
modulations at the single-cell level.
Herein we have focused our studies using CyTOF on the effects
of GO, one of the most recent biomedically promising
nanomaterials, on primary immune cells. Thanks to this
advanced technology, conﬁrmed by classical ﬂow cytometry
methods, we report that amino functionalization improves the
biocompatibility of GO. Moreover, GONH2 was found to induce
a cell-speciﬁc activation of T cells, DCs, and monocytes, which
were polarized to sustain a M1/Th1 immune response. The
positive impact of nanomaterials on speciﬁc immune cells can
serve as a starting point for the development of nanoscale
platforms in medicine as immunotherapeutics, vaccine carrier,
and nanoadjuvant tools27. Our pilot study paves the way for the
future use of single-cell mass cytometry for a deep characteriza-
tion of immune responses to any type of nanomaterials useful for
biomedical applications.
Methods
Applied strategy for GO and functionalized GONH2 synthesis. GO was pre-
pared using a modiﬁed Hummers’ method previously reported by Ali-Boucetta
et al.80 Brieﬂy, 0.2 g of graphite ﬂakes (Barnwell, UK) was added to 0.1 g of NaNO3
in 4.6 ml of 96% H2SO4. After obtaining a homogenous dispersion, 0.6 g of KMnO4
was slowly added. The temperature was carefully controlled during the reaction
and kept between 98 and 100 °C. The mixture was then diluted with 25 ml of
deionized H2O. To reduce residual KMnO4, MnO2, and Mn2O7 we slowly added a
solution of 3% H2O2. The obtained graphitic oxide suspension was further exfo-
liated and puriﬁed by several centrifugation steps until the pH of the supernatant
was around 7. Finally, we extracted and diluted the viscous orange/brown gel-like
layer of pure GO using MilliQ water.
2,2′-(ethylenedioxy)bis(ethylamine) (410 µl) was added to a 20 ml of a GO
dispersion (1 mgml−1) in deionized water, and the mixture was stirred for 2 days at
room temperature. The solution was then ﬁltered using an Omnipore
polytetraﬂuoroethylene (PTFE) membrane (0.45 µm, Millipore). The solid was
dispersed in methanol (100 ml), sonicated for 2 min and ﬁltered again. This
procedure was repeated with DMF and methanol. The solid was dispersed in
deionized water and dialyzed against deionized water using a dialysis membrane of
MWCO 12–14,000 Da.
Characterizations of the materials. For TEM characterization, 20 μl of sample
(100 μg ml−1) was deposited on a carbon-coated copper grid (Electron Microscopy
Services, USA). Excess material was removed by ﬁlter paper. Imaging was per-
formed using a FEI Tecnai 12 BioTWIN microscope (Techni, Netherlands) at an
acceleration voltage of 100 kV. Images were taken with a Gatan Orius SC1000 CCD
camera (GATAN, UK). Lateral size distributions were carried out using ImageJ
software after counting the lateral dimension of more than 100 individual GO
sheets from several TEM images. For AFM, freshly cleaved mica (Agar Scientiﬁc,
UK) was used as a substrate. Non-functionalized GO samples required a pre-
coating step of the negatively charged mica surface with 20 μl of 0.01% poly-L-
lysine (Sigma-Aldrich, UK). All samples were prepared by depositing 20 μl aliquots
of the respective GO dispersions (100 μg ml−1) on the mica substrates and allowing
them to adsorb for 2 min. Unbound structures were removed by gentle washing
with 2 ml of MilliQ water and samples were left to dry at 37 °C. AFM images were
acquired in air using a Multimode 8 atomic force microscope (Bruker, UK) in
tapping mode, using an OTESPA tip (Bruker, UK) mounted on a tapping mode
silicon cantilever with a typical resonant frequency of 300 kHz. Areas corre-
sponding to 512 × 512 points were scanned at a rate of 1 Hz, using an integral gain
of 1 and a proportional gain of 5; amplitude set point values were approximately
constant across all measurements. The acquired height images were processed
using the Nanoscope Analysis software (Version 1.4, Bruker, UK) in order to assess
lateral dimensions and thickness of the GO samples. A drop of the original GO
dispersions was placed onto a Tensor 27 FT-IR spectrometer (Bruker, UK)
equipped with a 3000 Series High Stability Temperature Controller with RS232
Control (Specac, UK) and a MKII Golden Gate Single Reﬂection ATR system
(Specac, UK) for measurements in ATR mode. The drop was allowed to dry on the
plate for 5 min at 60 °C, until a dry powder remained. Transmittance spectra of GO
were recorded by acquiring 32 scans between 700 and 4000 cm−1 with a resolution
of 4 cm−1. Data processing was completed using OriginPro 8.5.1 software (Origin
Lab, USA). For Raman spectroscopy, the samples were prepared for analysis by
drop casting 20 μl of sample (100 μg ml−1) dispersion onto a glass slide. The
samples were left to dry for at least 2 h at 37 °C. The spectra were collected using a
DXR micro-Raman spectrometer (Thermo Scientiﬁc, UK) using a λ= 633 nm
laser. The spectra were considered between 500 and 3400 cm−1, enabling visuali-
zation of the D and G bands. The spectra were collected at a laser power of 0.4 mW
at a magniﬁcation lens of ×50with 25 s exposure time, and averaged over ﬁve
different locations.
Immune cell puriﬁcation and cell culture maintenance. PBMCs were harvested
from ethylenediamine tetraacetic acid (EDTA)-venous blood from informed
healthy donors (25–50 years old) using a Ficoll-Paque (GE Healthcare, CA, USA)
standard separation protocol. Informed signed consent was obtained from all the
donors. The Ethics Committee of the University of Sassari reviewed and approved
all the protocols performed. All the experiments were carried out in accordance
with the approved guidelines. Jurkat and THP1 cell lines were supplied by the
ATCC (American Type Culture Collection) and have been tested for mycoplasma
contamination. Jurkat cells, THP1, and PBMCs were daily maintained in RPMI-
1640 medium added with FBS 10% and 1% of penicillin/streptomycin solution. At
least 1 × 106 cells for sample in each experiment were used. All the experiments
were performed in biological and technical triplicate.
Flow cytometric strategies for graphene interaction analysis. To evaluate the
cytotoxicity of GO and GONH2, PBMCs were incubated for 24 h at 37 °C with
increasing doses of each nanomaterial (5, 25, and 50 µg ml−1). Ethanol was used as
a positive control, while samples incubated with medium alone were used as
negative controls. Apoptotic and necrotic cells were analyzed with: Annexin-V-
FITC, PI, and 7AAD dye (Invitrogen, CA, USA).
To analyze the PBMCs activation after treatment with GO and GONH2,
experiments were performed with an intermediate concentration of 50 µg ml−1.
After 24 h of incubation, cells were stained to identify immune cell populations and
immune activation markers. CD25 and CD69 (APC-conjugated anti-CD25, 2A3
clone; PE-conjugated anti-CD69, L78 clone; BD Bioscience, CA, USA) were used as
activation markers. Concanavalin A (ConA, 10 μg ml−1) and lipopolysaccharides
(LPS, 2 μg ml−1, Missouri, USA) were used as positive controls (Sigma-Aldrich,
Missouri, USA). Staining was performed in the dark for 20 min. Cells were
analyzed by ﬂow cytometry (FACS Canto II, BD Bioscience, CA, USA).
Graphene impact analysis using single-cell mass cytometry. Single-cell mass
cytometry analysis was performed using puriﬁed PBMCs obtained as described
above. PBMCs were seeded at a concentrations of 3 × 106 cells per well (six multi-
well plates) and treated with GO and GONH2 at the ﬁxed concentration of 50 µg
ml−1 for 24 h. After the incubation, cells were harvested and washed with
phosphate-buffered saline (PBS). Before the staining, cells were incubated for 5 min
with Cisplatin-194Pt to a ﬁnal concentration of 1 µM. After the incubation, cells
were washed with Maxpar Cell Staining Buffer using ﬁve times the volume of the
starting cell suspension.
Cells were then stained using Maxpar Human Peripheral Blood Phenotyping
and Human Intracellular Cytokine I Panel Kits (Fluidigm, CA, USA) following the
manufacturer staining protocol for cell surface and cytoplasmic/secreted markers.
Brieﬂy, cells were harvested and resuspended in 50 μl of Maxpar Cell Staining
Buffer into 15 ml polystyrene tubes for each sample. The surface marker antibody
cocktail (dilution of 1:100 for each antibody) was added to each tube (ﬁnal volume
100 µl). Samples were mixed and incubated for 30 min at room temperature. After
incubation, the samples were washed twice with Maxpar Cell Staining Buffer. Cells
were then ﬁxed by adding 1 ml of Maxpar Fix and Perm Buffer to each tube and
incubated for 10 min. After incubation, cells were washed twice with Maxpar Fix
and Perm Buffer and centrifuged for 5 min at 800×g. Cells were then suspended in
50 μl of Maxpar Fix and Perm Buffer and incubated as described above with
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-01015-3 ARTICLE
NATURE COMMUNICATIONS |8:  1109 |DOI: 10.1038/s41467-017-01015-3 |www.nature.com/naturecommunications 11
cytoplasmic/secreted antibody cocktail (dilution of 1:100 for each antibody ﬁnal
volume 100 µl). After the incubation, cells were washed twice with Maxpar Cell
Staining Buffer and incubated with Cell-ID Intercalator-Ir solution at the ﬁnal
concentration of 125 nM into Maxpar Fix and Perm Buffer for 5 min. Each sample
was then washed twice with Maxpar Cell Staining Buffer and suspended with 2 ml
of ultrapure water. Before the data acquisition, each sample was ﬁltered into 5 ml
round bottom polystyrene tubes with a 30 μm cell strainer cap to remove possible
cell clusters or aggregates. Data were analyzed using mass cytometry platform
CyTOF2 (Fluidigm Corporation, CA, USA).
Hemolysis analysis. Hemolysis test was conducted following previously used
protocols53. Fresh human whole blood was taken from volunteer healthy donors
stabilized with 0.2% EDTA. Informed signed consent was obtained from all the
donors. The study was reviewed and approved by the Ethics Committee of the
University of Sassari. Serum was removed from blood samples by centrifugation at
200×g for 5 min. Resulting RBCs were washed ﬁve times with sterile isotonic PBS
and then diluted 10× with 0.2% EDTA. The hemolytic activity of GO and GONH2
at different concentrations (5, 25, 50, 100 µg ml−1) was determined by the incu-
bation of graphenes with the RBC suspension (0.2 ml, 4 × 108 cells·per ml) in a ﬁnal
volume of 1 ml, completed with PBS. After vortexing, the mixtures were left at
room temperature for 2 h, Intact RBCs were removed by centrifugation. A
microplate reader (Sunrise, Tecan) measured the absorbance (A) of the hemoglobin
in the supernatant at 570 nm, with the absorbance at 620 nm as a reference.
Genomic and cytokines analysis of treated immune cells. Gene expression
analysis was performed as previously described23, 25. Brieﬂy, total mRNA from
T-cell and monocyte cell lines treated with GO and GONH2 at the concentration of
50 µg ml−1, was extracted with TriZol Reagent (Invitrogen, CA, USA) and puriﬁed
with the RNAeasy Mini Kit (Qiagen, CA, USA). RNA purity was assessed using the
Bioanalyzer 2100 (Agilent). Samples with RIN (RNA Integrity Number) < 8 were
discarded. About 1 μg of RNA was converted in cRNA and labeled using the
Illumina totalPrep RNA Ampliﬁcation Kit, (Ambion, CA, USA). Biotinylated
cRNA was hybridized onto the Illumina HumanHT-12 v4 chip (Illumina, Inc., CA,
USA). Probe intensity and gene expression data were generated using the Illumina
GenomeStudio software V2011.1 (Gene Expression Module V1.9.0).
The cytokine analysis was performed with MILLIPLEX MAP plex Cytokine Kit
(HCYTOMAG-60K, Millipore, MA, USA) (IL1β, TNFα, IL6, Rantes (CCL5)). Cell
culture supernatants from PBMCs of at least three experiments were used for the
analysis.
Gene expression data conﬁrmation using real-time PCR. Total RNA (1 µg) was
puriﬁed as described above, and reverse transcribed using the superscript IV
Reverse Transcription Kit (Invitrogen, CA, USA) following the manufacturer
protocol. Real-time PCR reaction was performed on an Applied Biosystems 7300
thermal cycler following the Taqman gene expression assay protocol. Applied
Biosystems real-time PCR master mix and the following premade Taqman probes
were used: GAPDH Hs99999905_m1 and ACTB Hs99999903_m1 as housekeeping
genes, IRF1 Hs00971966_g1, CCL3L3 Hs03407473_uh, CCL5 HS99999048_m1,
and IL1B Hs01555410_m1. All experiments were performed in triplicate. Gene
expression analysis was computed by the 2ΔΔcT method.
Gating strategy and statistical analysis methods applied. The analysis of
CyTOF data was performed as previously described by Bendall et al.48 Brieﬂy,
normalized, background subtracted FCS ﬁles were imported into Cytobank for
analysis. Cell events were gated excluding the cell debris, doublets, and dead cells
using the Cell-ID Intercalator-Ir and CIS. We deﬁned speciﬁc PBMC subsets and
subpopulations as reported in Supplementary Fig. 13, in detail: T cells (CD45+
CD3+), T helper (CD45+ CD3+ CD4+), T cytotoxic (CD45+ CD3+ CD8+), T
naive (CD45RA+ CD27+ CD38− HLADR−), T effector (CD45RA+ CD27− CD38−
HLADR−), T memory (CD45RA− CD27+ CD38− HLADR−), and activated
(CD38+ HLADR+), B cells (CD45+ CD19+), B naive (HLADR+ CD27−), B
memory (HLADR+ CD27+), plasma B (HLADR− CD38+), NK cells (CD45+
CD3− CD19− CD20− CD14− HLADR− CD38+ CD16+), monocytes (CD45+
CD3− CD19− CD20− CD14+ HLADR+), mDC (CD45+ CD3− CD19− CD20−
CD14− HLA− DR+ CD11c+ CD123−), and pDC (CD45+ CD3− CD19− CD20−
CD14− HLADR+ CD11c− CD123+). The heat map visualization comparing
marker ﬂuorescence of the treated population with mean ﬂuorescent intensity vs.
the untreated control was performed with Cytobank. Singlets-gated FCS ﬁles were
analyzed in Cytobank for spanning tree visualization and comparison. SPADE and
viSNE tools were employed. viSNE is a cytometry analysis tool implemented in
Cytobank that use t-stochastic neighbor embedding (t-SNE) representing indivi-
dual cells in a two- or three-dimensional plot, based on their relationships. To
construct the SPADE tree and the viSNE map, we used 11 cell surface markers
listed as follow: CD3, CD4, CD8a, CD19, CD14, CD16, CD11c, CD123, CD45RA,
CD27, and HLADR. Statistical analyses conﬁrming the robustness of the SPADE
data (as reported in Supplementary Table 1) were performed using a two-way
analysis of variance (ANOVA) and Tukey’s multiple comparison test of every
algorithm run performed.
Data analysis for ﬂow cytometry data were performed using FACS Diva
software (BD Bioscience CA, USA) and FlowJo (LLC, Oregon, USA). Statistical
analyses were performed using a two tale Student’s t-test and one-way ANOVA
test. Data with a P-value < 0.05 were considered statistically signiﬁcant. Data are
presented as mean± SD. Multiplex ELISA tests on isolated human primary PMBCs
were performed in samples from at least three different donors. Whole-genome
expression measurements, and analysis, were performed as previously described23.
Brieﬂy, whole-genome expression data were extracted and normalized using the
Illumina GenomeStudio software V2011.1 (Gene Expression Module V1.9.0). The
quality control analysis of the beadchips was performed with the same software.
Statistical analysis, visualization of gene expression data, and analysis with GOd
were performed using BRBArrayTools (http://linus.nci.nih.gov/BRB-ArrayTools.
html). All the genes differentially expressed among the two classes were identiﬁed
by using a multivariate permutation test with 80% conﬁdence and a false
discoveries rates < 5%. Finally, to visualize the expression levels of identiﬁed genes
for GO and GONH2 in relevant pathway charts, we used IPA (Qiagen, CA, USA).
Data availability. The gene expression data sets generated and analyzed during the
current study are available in Gene Expression Omnibus (GEO) database
(#GSE99929) and as supplementary data set ﬁles. Single-cell mass cytometry data
and all the other data supporting the ﬁndings of this study are available within this
article (and its Supplementary Information ﬁle), and from the corresponding
author upon reasonable request.
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